PRESCRIPTION MONOGRAPH

Compounded Active Ingredients: Minoxidil /Latanoprost
Form: Topical Solution

Drug Class:

- Minoxidil: Antihypertensive vasodilator
- Latanoprost: Prostaglandin F2α analog

Mechanism of Action[1,2,3]**:**

When compounded together, Minoxidil and Latanoprost have the potential to provide a multi-targeted approach that enhances overall hair growth and preservation. Together they are intended to work by:

- Stimulate vascular and follicular activity by opening potassium channels in dermal papilla cells, to enhance blood flow and nutrient delivery to follicles, promoting local growth factors.
- Prolong hair growth cycle, increasing follicular proliferation, pigmentation, and shaft thickness.

Indications Commonly Prescribed For:

- Androgenetic alopecia
- Cosmetic hair quality: To improve density, thickness, and retention.

Before Use: Let your healthcare provider know if you have any medication allergies before you take this compounded preparation. Let your healthcare provider know if you have any liver or kidney problems. Let your healthcare provider know of all supplements you are currently taking.

Contraindications:

- Hypersensitivity to any component.
- Scalp irritation or dermatitis where barrier is compromised
- Systemic absorption of high minoxidil concentrations may cause hypotension
- Significant cardiovascular disease or hypotension

Cautions: Let your healthcare provider know if you experience any adverse side effects. Benefits persist only while on therapy.

Warnings and Precautions:

- Initial shedding: Temporary increased shedding may occur during the first several weeks of minoxidil treatment as follicles transition.
- Systemic absorption risk: monitor for hypotension and tachycardia.
- Concurrent use with retinoids or acids may increase scalp sensitivity—stagger products.
- Scalp conditions**:** Use with caution with psoriasis, eczema, or other compromised barrier.
- Can darken skin/hair at treated sites.
- Treatment discontinuation: Benefits from minoxidil are generally not permanent after therapy is stopped. Newly maintained or regrown hair may gradually be lost over several months as follicles return toward their untreated growth pattern.
- Eye exposure: Unintended eye exposure should be avoided. Chronic ocular exposure can cause iris pigmentation, eyelash changes, conjunctival redness, and other ocular effects.

Compounded medications are not FDA-approved and may differ in risks, benefits, and side effects from FDA-approved products. These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease or condition and do not indicate any claims of safety or efficacy. Individual results may vary.

PRESCRIPTION MONOGRAPH

Adverse Reactions: If you experience any side effects or adverse reactions, including those not listed, please contact your healthcare provider. Seek emergency care if symptoms are severe.

Common:

- Mild skin irritation, redness
- Hyperpigmentation
- Itching, Dryness
- Initial shedding
- Flaking, scaling
- Unwanted facial hair growth
- Contact dermatitis
- Folliculitis
- Headache, dizziness

Rare:

- Changes in blood pressure
- Edema
- Tachycardia, arrythmia
- Chest pain
- Palpitations
- Eye irritation or redness
- Increased iris pigmentation
- Eyelash growth or thickening
- Eyelid pigmentation changes

Interactions:

- Concurrent strong vasodilators or antihypertensives may have additive hypotensive effect if absorption is higher than expected.
- Avoid concurrent scalp irritants (retinoids, acids).
- Additive antiandrogen effect with spironolactone or other antiandrogens.
- Other prostaglandin analogs: Concurrent ophthalmic or topical prostaglandin therapy may increase prostaglandin-related effects. Treatment should be coordinated with the patient's prescriber, particularly when glaucoma medications are involved.

Use in Specific Populations:

- Pregnancy: Safety not established
- Pediatrics: Avoid unless under dermatologic supervision
- Geriatrics: Start with the lower minoxidil strength (2%) and monitor tolerability

Storage:

- Store in original container at room temperature (up to 30°C or 86°F)
- Store in a cool dry place away from heat, sunlight, and moisture

How to Use: This compounded preparation is provided as a topical solution in a spray bottle. Apply the directed number of sprays evenly to the affected areas of the scalp, usually once or twice daily as instructed by your provider. Gently massage the solution into the scalp if recommended. Wash your hands after application. Avoid getting the solution in your eyes, mouth, or on broken skin. If you miss a dose, apply it as soon as you remember, but do not double the application if it is nearly time for the next one. Consistent use is important, and desired results may take several weeks to become noticeable.

Monitoring Parameters:

- Skin/hair response over 8–12 weeks

Compounded medications are not FDA-approved and may differ in risks, benefits, and side effects from FDA-approved products. These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease or condition and do not indicate any claims of safety or efficacy. Individual results may vary.

Citations:

1. Li M, Marubayashi A, Nakaya Y, Fukui K, Arase S. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. *J Invest Dermatol*. 2001;117(6):1594-1600. doi:10.1046/j.0022-202X.2001.01570.x
2. Jiang S, Hao Z, Qi W, Wang Z, Zhou M, Guo N. The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis. *Front Med (Lausanne)*. 2023;10:1130623. doi:10.3389/fmed.2023.1130623s

Compounded medications are not FDA-approved and may differ in risks, benefits, and side effects from FDA-approved products. These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease or condition and do not indicate any claims of safety or efficacy. Individual results may vary.